MGEN News and Press, Miragen Therapeutics Inc. From 07/16/19

Gainers:  Immuron (NASDAQ: IMRN ) +81% . Blue Apron Holdings (NYSE: APRN ) +49% . Moxian (NASDAQ: MOXC ) +35% . GAIN Capital Holdings (NYSE: GCAP ) +32% . Lonestar Resources (NASDAQ: LONE ) +19% . AVROBIO (NASDAQ: AVRO ) +17% . Dolphin Entertainment (NASDAQ: DLPN ) +16% . Bio-P...

The following slide deck was published by Miragen Therapeutics, Inc. in conjunction with this Read more ...

BOULDER, Colo., May 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, announced today that William S. Marshall, Ph.D., President and Chief Execu...

BOULDER, Colo., May 21, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that it will report new data demonstrating that systemic administration ...

Soliton ( SOLY ) had a recent Reg A+ IPO in February 2019, with an unproven device that is supposed to assist a laser with tattoo and cellulite removal. SOLY is a relentless PR machine that we believe will end very badly for shareholders who think they are holding a solid investment. The compa...

miRagen Therapeutics, Inc. (MGEN) Q1 2019 Results Earnings Conference Call May 08, 2019 04:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Bill Marshall - President and Chief Executive Officer Jason Leverone - Chief Financial Officer Paul Rubin - Executive Vice Presi...

Miragen Therapeutics (NASDAQ: MGEN ): Q1 GAAP EPS of -$0.38 misses by $0.04 . More news on: Miragen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Initiated patient dosing in the SOLAR Phase 2 trial for cobomarsen Released updated clinical data from the Phase 1 trial of cobomarsen in ATLL patients Released data from preclinical studies showing the antifibrotic effects of remlarsen in corneal injury $51.0 million in cash,...

Portola Pharmaceuticals ( PTLA ) - The company announced that the European Commission granted conditional Marketing Authorization for Ondexxya (andexanet alfa) to be used in adult patients treated with the Factor Xa inhibitor apixaban or rivaroxaban when reversal of anticoagulation is needed...

Thinly traded nano cap miRagen Therapeutics (NASDAQ: MGEN ) is up  8%  premarket on light volume in reaction to positive preclinical data on remlarsen, a microRNA-29 replacement, in a rat model of corneal ulceration. The results are being presented today at the Association for Re...